Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
ABOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $4.28
Previous CloseN/A
Volume101.31K
Average Volume (3M)214.69K
Market Cap
$69.69M
Enterprise Value-$21.36M
Total Cash (Recent Filing)-$6.55M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Mar 31, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding60,079,777
10 Day Avg. Volume208,263
30 Day Avg. Volume214,695
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14419.15
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.50
Enterprise Value/Ebitda0.28
Forecast
1Y Price Target
$12.00Price Target Upside908.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Acumen Pharmaceuticals News
PremiumCompany Announcements
Acumen Pharmaceuticals Advances Alzheimer’s Treatment Efforts
PremiumCompany Announcements
Acumen Pharmaceuticals Completes Enrollment for Phase 2 Study
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe INTERCEPT-AD trial data shows sabirnetug has a remarkable impact on plaque clearance with a differentiated safety profile.
Market PositionSabirnetug is seen as having potential as a best-in-class alternative to existing Alzheimer’s treatments, such as Leqembi and Kisunla.
Safety ProfileThe safety profile of sabirnetug, with no ARIA-E in APOE4 homozygotes, is promising despite the small trial size.
Bears Say
Screening ChallengesThe use of ptau217 screening assays has effectively enrolled and enriched amyloid positive patients for the ALTITUDE-AD, reducing negative screening by nearly 50%.
Trial SizeThe safety profile of sabirnetug is promising despite the small trial size.
---
Ownership Overview
27.76% Insiders
11.06% Mutual Funds
41.87% Other Institutional Investors
13.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $1.10 and its highest was $4.28 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Acumen Pharmaceuticals’s market cap is $69.69M.
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is Mar 31, 2025 which is in 3 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.362 by -$0.138.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate is -0.49.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 60,079,777 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.362. Following the earnings report the stock price went down -16.77%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Currently, no hedge funds are holding shares in ABOS
---
Acumen Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (908.40% Upside)
$12.00 (908.40% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.06%
12-Months-Change
Fundamentals
Return on Equity
-32.83%
Trailing 12-Months
Asset Growth
-6.77%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
---
ABOS Company Deck
---
ABOS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with rapid progress in clinical trials, strong financial management, and strategic leadership appointments, although it acknowledges increased R&D expenses and a net loss.Read More>---
ABOS Stock 12 Month Forecast
Average Price Target
$12.00
▲(908.40% Upside)
Technical Analysis
Best Analysts Covering ABOS
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-45.95%
reiterated a buy rating 5 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -45.95% per trade.
---